Migraine Archives - Neurology Advisor

A smartphone application delivering guided progressive muscle relaxation was a both an accessible and acceptable form of therapy for patients with migraine.

Migraine and Headache

Researchers Look to Building Better Prediction Model for Episodic Migraine Attacks

By

Brandon May

November 23, 2020

During the study, participants completed a survey every evening pertaining to migraine occurrence and possible migraine predictors on an iPhone specific application.

Migraine and Headache

NDA Submitted for Novel Intranasal DHE for Migraine

By

Brian Park, PharmD

November 16, 2020

INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.

Migraine and Headache

The Role of Renin-Angiotensin System in the Pathophysiology of Migraine

By

Amit Akirov, MD

November 13, 2020

While it does not influence migraine severity, the renin-angiotensin system (RAS) has an important role in the pathophysiology of migraine.

Migraine and Headache

Occipital Nerve Stimulation Produces Lasting Improvements in Refractory Chronic Cluster Headache

By

Brandon May

November 11, 2020

Occipital nerve stimulation has been proposed to treat refractory chronic cluster headache but this study aimed to evaluate ONS long-term efficacy in rCCH.

Migraine and Headache

Erenumab Bests Topiramate in Head-to-Head Migraine Prevention Study

By

Brian Park, PharmD

November 5, 2020

The HER-MES study included 777 adult patients suffering from at least 4 migraine days/month and who were naïve to, not suitable for, or had previously failed up to 3 prophylactic treatments.

Migraine and Headache

Chronic Migraine: Fewer Monthly Migraine Days With Eptinezumab Infusion

By

Jessica Nye, PhD

November 3, 2020

This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.

Migraine and Headache

FDA Rejects Qtrypta NDA for Acute Treatment of Migraine

By

Brian Park, PharmD

October 27, 2020

Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.